Improving cell therapies through advanced single-cell sequencing technology
A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies
['FUNDING_SBIR_1'] · SANSIMEON, INC · NIH-10822508
This study is looking at a new way to improve cancer treatments like CAR-T therapy by examining a lot more immune cells from patients, which could help make these therapies work better and be more affordable for everyone.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SANSIMEON, INC (nih funded) |
| Locations | 1 site (FREMONT, UNITED STATES) |
| Trial ID | NIH-10822508 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing immunotherapies, such as CAR-T cell therapies, by utilizing a novel single-cell sequencing (SC-seq) approach that significantly increases the number of cells analyzed. By mapping a patient's immune response at the single-cell level, the research aims to improve the effectiveness and affordability of these therapies. The proposed method can process over 100 million cells, which is a substantial improvement over current technologies that are limited to 1 million cells per experiment. This advancement could lead to better-targeted treatments and a deeper understanding of immune responses in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are undergoing treatment for cancers that may benefit from advanced immunotherapy.
Not a fit: Patients who are not diagnosed with cancer or those who are under 21 years old may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and accessible immunotherapies for patients with various cancers.
How similar studies have performed: Other research has shown promise in using single-cell sequencing for immune profiling, but this specific scalable approach is novel and has not been widely tested.
Where this research is happening
FREMONT, UNITED STATES
- SANSIMEON, INC — FREMONT, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPUHLER, PHILIPP STEFAN — SANSIMEON, INC
- Study coordinator: SPUHLER, PHILIPP STEFAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.